Cerevance's solengepras failed to meet its primary endpoint in the ASCEND trial, which sought to evaluate it as a monotherapy ...

AC Immune has reported additional interim safety and positive immunogenicity outcomes from its placebo-controlled Phase II ...

Higher doses of the company’s multiple sclerosis drug failed to show additional benefit in slowing rates of disability ...

Antag Therapeutics has commenced a first-in-human, double-blind Phase Ia trial of the GIPR antagonist, AT-7687, intended for ...

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), Roche announced topline results ...

IoT helps to decentralise clinical trials while providing pharmaceutical companies with a higher return on investment.

Beigene has chosen to scrap ociperlimab after analysis found the lung cancer drug wouldn't its endpoint in extending overall survival.

BioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...

Patient engagement through advisory boards, surveys, and listening sessions can help address industry challenges like trial ...

Initial results from the ongoing trial saw one patient achieving a complete response in the trial combining Tovecimig with ...

Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 in adults with idiopathic ...

The pivotal, Phase III study will evaluate the change in average daily “OFF” time in Parkinson's patients dosed with ...